• ViroVet successful with second vaccine based on new vaccine technology, Rega Institute assesses development of human version

    Monday March 22nd 2021

  • Consortium led by eTheRNA immunotherapies awarded EU Commission TIGER Grant of EUR 6.9 million

    Monday March 22nd 2021

  • Galapagos reports primary endpoint for the ongoing filgotinib MANTA and MANTA-RAy safety studies

    Thursday March 4th 2021

  • Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

    Thursday February 11th 2021

  • VUB scientist Mathieu Vinken coordinates prestigious European research into animal-free methods for testing chemical substances

    Wednesday February 3rd 2021

  • argenx announces “GO” Decision in ADHERE trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy following interim analysis

    Tuesday February 2nd 2021

  • Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

    Tuesday January 12th 2021

  • Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study

    Tuesday December 22nd 2020

  • Your news here?

  • Mithra announces positive DSMB safety review and continuation of its Phase III Clinical Program Donesta® in menopause

    Wednesday December 16th 2020

  • Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

    Thursday December 3rd 2020

  • reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

    Thursday December 3rd 2020


Strategic Partners